|
Unit:
|
Logistics Industry Department of Investment Promotion Committee, Pingtan Comprehensive Experimental Zone
|
|
|
Project Area:
|
pingtan Pingtan Cross-Strait Medical and Health Industrial Park; Haixi (West Coast) Entry-Exit Animal-Plant Quarantine Center; Drug Safety Evaluation Center (Laboratory Animal Center)
|
|
|
Industry:
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode:
|
Collaborate
|
|
|
Nature of Project:
|
Encourage
|
|
|
Working Progress in Prior Period:
|
none
|
|
|
Total Investment:
|
discussed in detai
|
|
|
Expected to Attract Investment:
|
discussed in detai
|
|
|
Benefit Analysis:
|
none
|
|
|
Reason and Condition:
|
none
|
|
|
Content and Scale:
|
1. Pingtan Cross-Strait Medical and Health Industrial Park: plans to introduce enterprises of biomedical R&D, production and sales for imports and exports of drugs, medical devices and cosmetics, as well as headquarter logistics, bonded R&D, and bonded processing.2. Haixi (West Coast) Entry-Exit Animal-Plant Quarantine Center: plans to introduce third-party technical service platforms for disease models of laboratory animals, non-clinical safety research on drugs and medical devices, testing, and drug screening and evaluation.3. Drug Safety Evaluation Center: plans to introduce third-party technical service platforms engaging in disease models of laboratory animals, non-clinical safety research on drugs and medical devices, testing, and drug screening and evaluation.
|
|
|
Others:
|
none
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.